Dr. Reddy's Laboratories Limited

Nippon India Mutual Fund decreased its stake in Dr. Reddy's Laboratories by selling 3,705,462 shares. The fund's holding changed from 15,130,303 shares to 11,424,841 shares.

A leading India-based pharmaceutical company, Dr Reddy's Laboratories manufactures and distributes Active Pharmaceutical Ingredients, generic medicines, biosimilars, and differentiated formulations across multiple therapeutic areas. The company operates custom pharmaceutical services and serves patients in markets worldwide. Its integrated operations span drug discovery, development, manufacturing, and commercialization of innovative and generic pharmaceuticals for diverse healthcare needs.

India's fifth-largest AMC with over Rs 6 lakh crore in AUM, backed by Japan's Nippon Life Insurance which holds majority stake. Formerly Reliance MF, rebranded in 2019 after Nippon's acquisition. Sailesh Raj Bhan has run the equity book for over two decades and is one of India's most experienced active managers. Known for sector rotational calls and a deep research bench.